BMY, CELG And AMGN, 3 Drugs Stocks Pushing The Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 100 points (0.7%) at 14,812 as of Monday, April 29, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,173 issues advancing vs. 733 declining with 124 unchanged.

The Drugs industry currently sits up 0.9% versus the S&P 500, which is up 0.8%. A company within the industry that fell today was Eli Lilly and Company ( LLY), up 0.69. Top gainers within the industry include Watson Pharmaceuticals ( WPI), up 5.4%, Actavis ( ACT), up 5.5%, Novo Nordisk A/S ( NVO), up 2.1%, Pfizer ( PFE), up 1.4% and AstraZeneca ( AZN), up 1.1%.

TheStreet Ratings group would like to highlight 3 stocks pushing the industry lower today:

3. Bristol-Myers Squibb Company ( BMY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Bristol-Myers Squibb Company is down $0.36 (-0.9%) to $39.92 on light volume Thus far, 3.2 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.5 million shares. The stock has ranged in price between $39.81-$40.28 after having opened the day at $40.13 as compared to the previous trading day's close of $40.28.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $66.1 billion and is part of the health care sector. The company has a P/E ratio of 45.2, above the S&P 500 P/E ratio of 17.7. Shares are up 23.6% year to date as of the close of trading on Friday.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Celgene Corporation ( CELG) is down $0.97 (-0.8%) to $119.37 on average volume Thus far, 1.6 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $119.01-$120.92 after having opened the day at $120.28 as compared to the previous trading day's close of $120.34.

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $49.4 billion and is part of the health care sector. The company has a P/E ratio of 32.9, above the S&P 500 P/E ratio of 17.7. Shares are up 50.3% year to date as of the close of trading on Friday.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Amgen ( AMGN) is down $1.03 (-0.9%) to $107.35 on light volume Thus far, 1.6 million shares of Amgen exchanged hands as compared to its average daily volume of 5.3 million shares. The stock has ranged in price between $106.86-$108.38 after having opened the day at $108.15 as compared to the previous trading day's close of $108.38.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $81.4 billion and is part of the health care sector. The company has a P/E ratio of 18.5, above the S&P 500 P/E ratio of 17.7. Shares are up 26.1% year to date as of the close of trading on Friday.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit